Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 1, 2002, Pages 99-104

  Caron, Ph ^a   Beckers, A ^b   Cullen, D R ^c   Goth, M I ^d   Gutt, B ^e   Laurberg, P ^f   Pico, A M ^g   Valimaki, M ^h   Zgliczynski, W ⁱ  

^a CHU RANGUEIL   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ Department of Neonatology   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LANREOTIDE AUTOGEL; LONG ACTING DRUG; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACROMEGALY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; STEADY STATE; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0036148030     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.1.8153     Document Type: Article

References (22)

1. Long term efficacy of sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the international multicentre acromegaly study group
2. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years
3. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients
4. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
5. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study
6. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients treated with continuous subcutaneous infusion of octreotide (SMS 201-995)
7. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
8. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)
9. Octreotide
10. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients
11. The growth hormone responses to octreotide in acromegaly correlate with adenoma sandostatin receptors
12. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cylase
13. Influence de la dose et des modalités d'administration du BIM 23014 sur la sécrétion d'hormone de croissance de l'acromégale
14. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995)
15. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
16. Sandostatin LAR in acromegalic patients: Long-term treatment
17. Results of a European multicentre study with Sandostatin LAR in acromegalic patients
18. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients-a clinical research center study
19. Criteria for cure of acromegaly: A consensus statement
20. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: Clinical implications
21. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide
22. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly